 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
Mark, here is info I promised you on Martek NASD symbol MATK Martek develpos and produces products from microalgae. They have one of world's largest microalgae libraries which is currently being explored for products. For example Merck and Genetics Institute are screening their libraries for potential pharmaceuticals at this time. This arrangement is much like the gene database that Human Genome Sciences has for genes. This processs could lead to big things in the future but meanwhile there is real product beginning to sell that is the cash cow story. MATK has created a product called Formulaid from fatty acids and are using the product as an additive to baby formula. It's advantage is making baby formula have the same acids found in breast milk. What is incredible is the research which shows how breast fed babies have better health, sight and higher IQs when fed with breast milk. MATK's Formulaid will take the baby formula market by storm. Formulaid is REAL!!!!! They are making it today. They have already signed up Bristol Myers Squibb, American Home Products, Maabarot, Nutricia, Sandoz which together sell over 40%of all formula around the world. The remaining companies who sell the other 60% are highly likely to license the product as competitors use the product in their market. Currently MATK is ramping up production of Formulaid at a new $10M plant. Formulaid now in formula being sold in several European countries with more in very near term. US sales should begin starting this year. Phased start up is necessary because they couldn't supply all the demand by simultaneous startup everywhere, so production planned to stay ahead of each country as product is intoduced by formula licensee. There is NO ISSUE of this product being safe. Many tests have already confirmed. The approval in US will require only a generally recognized as safe (GRAS) approval which is a 90 day FDA process. What does it mean in profits???? MATK will get a 3% licence fee on sales from the formula companies. Estimated of revenues from making and licensing Formulaid is about $120 for the companies already signed. More after the "the other 60%" sign. As I see it this revenue is the CASH COW for MATK. High margin ongoing revenue from a product that should be used every year into the future. Investor Business Daily had a neat article on MATK Dec 4 1995. I could go on about other items on MATK but this should answer your questions about why I am so sure about this stock. Of course you should do your checking before investing on anything. More on MATK can be had from MATK investor relations guy Greg Lampf, 410 740 0081. | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |